ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1713

Defining Genetic Risk for Scleroderma Renal Crisis in RNA-Polymerase III Antibody Positive Patients

Edward Stern1, Sandra Guerra1, Harry Chinque1, David Gonzalez Serna2, Markella Ponticos1, Javier Martin2, Maureen D. Mayes3, Shervin Assassi4, Carmen Fonseca1 and Christopher Denton5, 1UCL Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom, 2Instituto de Parasitología y Biomedicina López-Neyra, Granada, Spain, 3Internal Medicine/Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, 4University of Texas McGovern Medical School, Houston, TX, 5Department of Rheumatology, University College London, Royal Free Hospital, London, United Kingdom

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: genetics, pathogenesis, Renal disease, scleroderma and systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Scleroderma renal crisis (SRC), characterised by accelerated hypertension and acute kidney injury, is a life-threatening complication of systemic sclerosis (SSc). Most SSc cases have a disease-specific circulating antibody, including the anti Scl-70, anti-centromere and anti RNA polymerase III (ARA) antibodies. Previous studies confirm ARA as a powerful serological predictor of SRC, and cases of SRC more than 5 years after the diagnosis of SSc are rare. We developed an innovative approach to identify genetic susceptibility loci for SRC, comparing ARA positive patients with and without the occurrence of SRC.

Methods:

From a well-characterised SSc cohort (n=415), we selected 100 ARA+ patients with more than 5 years of follow-up data. 50 had a history of SRC and 50 had not developed SRC. All cases were of northern European ancestry. Cases were genotyped using the Illumina Human Omni-express chip. Quality control checks were performed in PLINK (Hardy-Weinberg equilibrium p <0.001; genotyping rate >90%). Based on the results of logistic regression analysis, ten SNPs were put forward for validation in a separate US cohort of 256 ARA+ patients (40 SRC+), using ThermoFisher TaqMan genotyping probes. Immunohistochemistry (IHC) was performed on SRC biopsy samples to identify proteins associated with our genes of interest.

Results:

After quality control checks, 641,489 SNPs were analysed in the first cohort. In logistic regression analysis of our initial cohort, the SNPs within genes and gene regions most strongly associated with SRC were for POU2F1 (p=4.12 x 10-5), CTNND2 (p=2.92 x 10-5), HECW2 (p=2.71 x 10-5), GRIA3 (p=2.16 x 10-5) and GPATCH2L (p=2.06 x 10-5). The SNP within the GPATCH2L region was also significantly associated with SRC in our validation cohort (p=0.025). GPATCH2L polymorphisms have been associated with essential hypertension in previous GWAS analysis.

Polymorphisms in the CTNND2 gene have been demonstrated to be associated with pulmonary arterial hypertension, another vascular complication of SSc, in previous studies. We performed IHC for this protein on 8 renal biopsy samples from confirmed cases of SRC and 8 normal human kidney controls (see figure). Tubular epithelial staining was present in cases and controls. Glomerular staining was markedly increased in the SRC cases compared with controls, with 5 cases showing significant staining in this compartment compared with 0 controls (FisherÕs Exact p=0.026).

Conclusion:

A novel autoantibody-based extreme phenotype method identifies risk alleles for SRC within a rare disease cohort. Using genetic and histological validation methods we identify CTNND2 and GPATCH2L as candidates for investigation of SRC aetiopathogenesis.


Disclosure: E. Stern, None; S. Guerra, None; H. Chinque, None; D. Gonzalez Serna, None; M. Ponticos, None; J. Martin, None; M. D. Mayes, None; S. Assassi, None; C. Fonseca, None; C. Denton, Actelion, Pfizer, GlaxoSmithKline, Bayer, Sanofi-Aventis, Boehringer Ingelheim, Genentech-Roche, CSL Behring, Biogen, 5,Actelion, GlaxoSmithKline, Bayer, Genentech-Roche, CSL Behring, 2.

To cite this abstract in AMA style:

Stern E, Guerra S, Chinque H, Gonzalez Serna D, Ponticos M, Martin J, Mayes MD, Assassi S, Fonseca C, Denton C. Defining Genetic Risk for Scleroderma Renal Crisis in RNA-Polymerase III Antibody Positive Patients [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/defining-genetic-risk-for-scleroderma-renal-crisis-in-rna-polymerase-iii-antibody-positive-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/defining-genetic-risk-for-scleroderma-renal-crisis-in-rna-polymerase-iii-antibody-positive-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology